Journal
CANCER LETTERS
Volume 290, Issue 2, Pages 182-191Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.09.006
Keywords
CML; Bcr-Abl; T315I mutation; Imatinib; Celastrol; Apoptosis
Categories
Funding
- National High Technology Research and Development Program of China [2008AA02Z420]
- Major Research Plan of the National Natural Science Fund of China [90713036]
- National Basic Research Program of China [2009CB825506]
Ask authors/readers for more resources
T315I Bcr-Abl in chronic myelogenous leukemia (CML) is the most notorious point mutations to elicit acquired resistance to imatinib. In the present study, we investigated the effect of celastrol on CML cells bearing wild-type Bcr-Abl or T315I-mutant. The results revealed that celastrol potently downregulated the protein levels of Bcr-Abl, and inhibited the growth in CML cells in vitro and in nude mouse xenografts regardless of Bcr-Abl mutation status. Celastrol induced mitochondrial-dependent apoptosis. In conclusion, celastrol exhibits potent activity against CML cells bearing wild-type Bcr-Abl or -the T315I-mutant. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available